Payment overview · 2025
General Payments
$191.78
10 reported records · 5 companies
Healthcare provider profile · identity verified
Jorge Luis Torres, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ORLANDO, FL · NPI 1497189971
Verified facts
What the public records show
CMS Open Payments records show Jorge Luis Torres, MD received $191.78 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 43.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $84.08 | 43.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.88 | 21.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.33 | 15.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.43 | 10.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.06 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $191.78 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.88 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.88 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.88 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $30.33 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 89 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 545 | 196 |
| Atorvastatin Calcium | Atorvastatin Calcium | 450 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 433 | 167 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 116 |
| Losartan Potassium | Losartan Potassium | 334 | 127 |
| Gabapentin | Gabapentin | 247 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 244 | 88 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 237 | 92 |
| Glipizide Er | Glipizide | 236 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 90 |
| Omeprazole | Omeprazole | 200 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 66 |
| Metformin Hcl Er | Metformin Hcl | 184 | 66 |
| Ozempic | Semaglutide | 166 | 49 |
| Metformin Hcl | Metformin Hcl | 161 | 64 |
| Lisinopril | Lisinopril | 157 | 55 |
| Carvedilol | Carvedilol | 134 | 50 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 132 | 47 |
| Montelukast Sodium | Montelukast Sodium | 131 | 47 |
| Jardiance | Empagliflozin | 128 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 47 |
| Azithromycin | Azithromycin | 118 | 89 |
| Trazodone Hcl | Trazodone Hcl | 111 | 44 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 109 | 24 |
| Allopurinol | Allopurinol | 104 | 34 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 103 | 61 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 48 |
| Ketoconazole | Ketoconazole | 101 | 38 |
| Celecoxib | Celecoxib | 98 | 54 |
| Famotidine | Famotidine | 95 | 39 |
| Eliquis | Apixaban | 89 | 34 |
| Simvastatin | Simvastatin | 86 | 31 |
| Clotrimazole | Clotrimazole | 84 | 56 |
| Furosemide | Furosemide | 84 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 31 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 79 | 30 |
| Buspirone Hcl | Buspirone Hcl | 78 | 31 |
| Azelastine Hcl | Azelastine Hcl | 74 | 42 |
| Ezetimibe | Ezetimibe | 74 | 32 |
| Methylprednisolone | Methylprednisolone | 73 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 28 |
| Bumetanide | Bumetanide | 71 | 27 |
| Colchicine | Colchicine | 71 | 36 |
| Rybelsus | Semaglutide | 71 | 17 |
| Ondansetron Odt | Ondansetron | 70 | 41 |
| Alendronate Sodium | Alendronate Sodium | 66 | 29 |
| Memantine Hcl | Memantine Hcl | 65 | 23 |
| Sucralfate | Sucralfate | 64 | 32 |
| Valsartan | Valsartan | 64 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 25 |
| Clonidine | Clonidine | 60 | 17 |
| Fluconazole | Fluconazole | 60 | 39 |
| Nitroglycerin | Nitroglycerin | 59 | 29 |
| Mupirocin | Mupirocin | 58 | 40 |
| Farxiga | Dapagliflozin Propanediol | 56 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 19 |
| Methotrexate | Methotrexate Sodium | 53 | 20 |
| Ciclopirox | Ciclopirox | 52 | 20 |
| Temazepam | Temazepam | 52 | suppressed |
| Nifedipine Er | Nifedipine | 51 | 24 |
| Mirtazapine | Mirtazapine | 50 | 21 |
| Atenolol | Atenolol | 49 | 17 |
| Meclizine Hcl | Meclizine Hcl | 49 | 25 |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 19 |
| Baclofen | Baclofen | 46 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 23 |
| Donepezil Hcl | Donepezil Hcl | 45 | 20 |
| Potassium Chloride | Potassium Chloride | 45 | 16 |
| Bupropion Xl | Bupropion Hcl | 44 | 18 |
| Ibuprofen | Ibuprofen | 43 | 16 |
| Alprazolam | Alprazolam | 42 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 41 | 17 |
| Sertraline Hcl | Sertraline Hcl | 39 | 14 |
| Ammonium Lactate | Ammonium Lactate | 37 | 18 |
| Finasteride | Finasteride | 37 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 12 |
| Spironolactone | Spironolactone | 36 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 12 |
| Valacyclovir | Valacyclovir Hcl | 34 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 15 |
| Fenofibrate | Fenofibrate,micronized | 33 | 12 |
| Methocarbamol | Methocarbamol | 33 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 30 |
| Lactulose | Lactulose | 32 | 24 |
| Clonidine Hcl | Clonidine Hcl | 31 | 16 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Liothyronine Sodium | Liothyronine Sodium | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 25 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 13 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Benzonatate | Benzonatate | 23 | 19 |
| Latanoprost | Latanoprost | 23 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Pentoxifylline | Pentoxifylline | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Tresiba | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Erythromycin | Erythromycin Base | 11 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $191.78 · 10 records | PFIZER INC. | CREON, ELIQUIS, KRYSTEXXA, LINZESS, MOUNJARO, NURTEC ODT, TRELEGY ELLIPTA, VIBERZI, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error